XLH

Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), a clinical-stage bio-pharmaceutical company, were trading higher by more than 7 percent Wednesday in reaction to an encouraging update regarding its Burosumab therapy which is used by patients with X-linked hypophosphatemia (XLH) in a Phase 3...

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) revealed positive interim data from the second-stage study of KRN23 for tumor-induced osteomalacia (TIO) treatment. The company indicated its interim data at 24 weeks from the first eight patients showed KRN23 improved serum phosphorus levels and bone...